Coherus Oncology

Approved

Redwood City, United StatesFounded 2010coherus.com

Coherus Oncology is dedicated to extending patient survival through a portfolio of innovative immuno-oncology (I-O) combination therapies. The company has successfully commercialized LOQTORZI® and is advancing multiple clinical-stage candidates, including tagmokitug (anti-CCR8) and casdozokitug (IL-27 antagonist), across various solid tumors. With a leadership team of seasoned industry veterans and a strategic focus on novel I-O mechanisms, Coherus aims to transform cancer treatment by addressing key resistance pathways in the tumor microenvironment.

Founded

2010

Focus

BiologicsBiosimilars

AI Company Overview

Technology Platform

Focus on developing monoclonal antibody therapies targeting immuno-oncology pathways, with a strategic emphasis on combination therapies that pair an anti-PD-1 backbone with novel mechanisms to overcome resistance in the tumor microenvironment.

Funding History

Total raised: $315M

PIPE$150MUndisclosedJun 15, 2021

IPO$75MUndisclosedOct 2, 2014

Series B$55MBay City CapitalJun 15, 2012

Series A$35MVivo VenturesJun 15, 2010

Opportunities

Significant growth opportunities exist in expanding LOQTORZI into new indications and advancing novel combinations like tagmokitug and casdozokitug into larger solid tumor markets such as colorectal cancer and hepatocellular carcinoma.

Positive clinical data could also make Coherus an attractive partner or acquisition target for larger pharmaceutical companies seeking to bolster their immuno-oncology portfolios.

Risk Factors

Key risks include clinical trial failures for lead pipeline candidates, intense competition from larger pharmaceutical companies with greater resources, potential challenges in commercial execution as a mid-sized biotech, and the ongoing need for capital to fund late-stage development, which could lead to shareholder dilution.

Competitive Landscape

Coherus competes in the crowded immuno-oncology space dominated by Merck, Bristol Myers Squibb, and Roche. Its differentiation lies in focusing on niche indications (e.g., NPC) with its approved therapy and developing next-generation combinations targeting novel pathways like CCR8 and IL-27, which are not yet addressed by market leaders.